NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer

被引：0

作者：

Fehrenbacher, Louis

Jeong, Jong-Hyeon

Rastogi, Priya

Geyer, Charles E.

Paik, Soonmyung

Ganz, Patricia A.

Land, Stephanie R.

Costantino, Joseph P.

Swain, Sandra M.

Mamounas, Eleftherios P.

Wolmark, Norman

机构：

[1] Natl Surg Adjuvant Breast & Bowel Project, Vallejo, CA USA

[2] Kaiser Permanente Calif, Vallejo, CA USA

[3] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA

[4] NSABP, Pittsburgh, PA USA

[5] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA

[6] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

[7] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Div Canc Prevent & Control Res, Los Angeles, CA 90024 USA

[8] NSABP Biostat Ctr, Pittsburgh, PA USA

[9] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Natl Surg Adjuvant Breast & Bowel Project,Biostat, Pittsburgh, PA 15261 USA

[10] NSABP, Washington, DC USA

[11] MedStar Washington Hosp Ctr, Washington Canc Inst, Washington, DC USA

[12] MD Anderson Canc Ctr Orlando, Orlando, FL USA

[13] Allegheny Gen Hosp, Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA 15212 USA

[14] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS1139

引用

页数：1

共 50 条

[21] A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer:: Final results
Rouëssé, J
De la Lande, B
Bertheault-Cvitkovic, F
Serin, D
Graïc, Y
Combe, M
Leduc, B
Lucas, V
Demange, L
Nguyen, TD
Castèra, D
Krzisch, C
Villet, R
Mouret-Fourme, E
Garbay, JR
Noguès, C
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (04): : 1072 - 1080
[22] Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial
Yang Yang
Yingjian He
Zhaoqing Fan
Xue Chen
Yiqiang Liu
Chao Zhang
Hongchuan Jiang
Xin Wang
Xiang Wang
Fei Xie
Shu Wang
Bin Luo
Hua Kang
Tao Wang
Zefei Jiang
Peng Yuan
Binhe Xu
Ling Xu
Yinhua Liu
Jinfeng Li
Yuntao Xie
Tianfeng Wang
Tao Ouyang
npj Breast Cancer, 9
[23] Adjuvant Trastuzumab Reduces Locoregional Recurrence in Women who Undergo Breast Conservation Therapy for Node-Negative HER2-Positive Breast Cancer
Kiess, A. P.
McArthur, H. L.
Mahoney, K.
Patil, S.
Morris, P. G.
Ho, A.
Hudis, C. A.
McCormick, B.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S98 - S98
[24] Abemaciclib plus endocrine therapy for hormone receptor- positive, HER2-negative, node-positive, high-risk, early breast cancer
Nozawa, Kazuki
Sawaki, Masataka
Iwata, Hiroji
LANCET ONCOLOGY, 2023, 24 (03): : E103 - E103
[25] Randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer (BC) comparing FAC with FAC followed by weekly paclitaxel: First efficacy analysis of the GEICAM/2003-02 trial
Martin, Miguel
Lluch, Ana
Ruiz, Amparo
Ruiz Borrego, Manuel
Barnadas, Agust
Gonzalez, Sonia
Calvo, Lourdes
Margeli Vila, Mireia
Anton, Antonio
Rodriguez-Lescure, Alvaro
Angel Segu-Palmer, Miguel
Munoz-Mateu, Montserrat
Dorca Ribugent, Joan
Manuel Lopez-Vega, Jose
Mendiola Fernandez, Cesar
Andres, Raquel
Plazaola, Arrate
Rodriguez, Cesar
Isabel Casas, Maria
Maria Carrasco, Eva
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[26] A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)
Tolaney, S. M.
Barry, W. T.
Dang, C. T.
Yardley, D. A.
Moy, B.
Marcom, P. K.
Albain, K. S.
Rugo, H. S.
Ellis, M.
Shapira, I.
Wolff, A. C.
Carey, L. A.
Overmoyer, B. A.
Partridge, A. H.
Guo, H.
Hudis, C. A.
Krop, I. E.
Burstein, H. J.
Winer, E. P.
CANCER RESEARCH, 2013, 73
[27] Randomized phase III trial comparing the sequential administration of docetaxel followed by epirubicin plus cyclophosphamide versus FE75C as adjuvant chemotherapy in axillary lymph node-positive breast cancer
Mavroudis, D.
Malamos, N.
Papakotoulas, P.
Adamou, A.
Christophyllakis, C.
Ziras, N.
Syrigos, K.
Kakolyris, S.
Kouroussis, C.
Georgoulias, V.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[28] 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study
Hudis, C
Fornier, M
Riccio, L
Lebwohl, D
Crown, J
Gilewski, T
Surbone, A
Currie, V
Seidman, A
Reichman, B
Moynahan, M
Raptis, G
Sklarin, N
Theodoulou, M
Weiselberg, L
Salvaggio, R
Panageas, KS
Yao, TJ
Norton, L
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1118 - 1126
[29] Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer
He, Xuexin
Ji, Jiali
Tian, Mei
Esteva, Francisco J.
Hortobagyi, Gabriel N.
Yeung, Sai-Ching Jim
CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7388 - 7395
[30] A phase III adjuvant trial of sequenced EC plus filgrastim plus epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21)
Burnell, M. J.
Levine, M. N.
Chapman, J. A.
Bramwell, V.
Vandenberg, T.
Chalchal, H. I.
Albain, K.
Perez, E.
Rugo, H.
Pritchard, K.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

← 1 2 3 4 5 →